Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

Evaluation of dynamic contrast-enhanced MRI biomarkers for stratified cancer medicine: How do permeability and perfusion vary between human tumours?

Little RA, Barjat H, Hare JI, Jenner M, Watson Y, Cheung S, Holliday K, Zhang W, O'Connor JPB, Barry ST, Puri S, Parker GJM, Waterton JC.

Magn Reson Imaging. 2018 Feb;46:98-105. doi: 10.1016/j.mri.2017.11.008. Epub 2017 Nov 14.

2.

Imaging biomarkers exist and they underpin clinical decision-making.

Waterton JC, McShane LM, O'Connor JPB.

Nat Rev Clin Oncol. 2017 Nov;14(11):694. doi: 10.1038/nrclinonc.2017.167. Epub 2017 Oct 17.

PMID:
29039425
3.

Implementing diffusion-weighted MRI for body imaging in prospective multicentre trials: current considerations and future perspectives.

deSouza NM, Winfield JM, Waterton JC, Weller A, Papoutsaki MV, Doran SJ, Collins DJ, Fournier L, Sullivan D, Chenevert T, Jackson A, Boss M, Trattnig S, Liu Y.

Eur Radiol. 2018 Mar;28(3):1118-1131. doi: 10.1007/s00330-017-4972-z. Epub 2017 Sep 27.

4.

Evaluation of non-contrast MRI biomarkers in lupus nephritis.

Skeoch S, Hubbard Cristinacce PL, Dobbs M, Naish J, Woodhouse N, Ho M, Waterton JC, Parker GJM, Bruce IN.

Clin Exp Rheumatol. 2017 Nov-Dec;35(6):954-958. Epub 2017 Aug 28.

PMID:
28850028
5.

Imaging biomarkers exist and they underpin clinical decision-making.

Waterton JC, McShane LM, O'Connor JPB.

Nat Rev Clin Oncol. 2017 Jul;14(7):452. doi: 10.1038/nrclinonc.2017.84. Epub 2017 Jun 13. No abstract available. Erratum in: Nat Rev Clin Oncol. 2017 Oct 17;:.

PMID:
28607515
6.

Imaging atherosclerosis in rheumatoid arthritis: evidence for increased prevalence, altered phenotype and a link between systemic and localised plaque inflammation.

Skeoch S, Cristinacce PLH, Williams H, Pemberton P, Xu D, Sun J, James J, Yuan C, Hatsukami T, Hockings PD, Alexander MY, Waterton JC, Bruce IN.

Sci Rep. 2017 Apr 11;7(1):827. doi: 10.1038/s41598-017-00989-w.

7.

Diffusion-weighted (DW) MRI in lung cancers: ADC test-retest repeatability.

Weller A, Papoutsaki MV, Waterton JC, Chiti A, Stroobants S, Kuijer J, Blackledge M, Morgan V, deSouza NM.

Eur Radiol. 2017 Nov;27(11):4552-4562. doi: 10.1007/s00330-017-4828-6. Epub 2017 Apr 10.

PMID:
28396997
8.

Repeatability and response to therapy of dynamic contrast-enhanced magnetic resonance imaging biomarkers in rheumatoid arthritis in a large multicentre trial setting.

Waterton JC, Ho M, Nordenmark LH, Jenkins M, DiCarlo J, Guillard G, Roberts C, Buonaccorsi G, Parker GJM, Bowes MA, Peterfy C, Kellner H, Taylor PC.

Eur Radiol. 2017 Sep;27(9):3662-3668. doi: 10.1007/s00330-017-4736-9. Epub 2017 Jan 23.

9.

Preclinical Applications of 3'-Deoxy-3'-[18F]Fluorothymidine in Oncology - A Systematic Review.

Schelhaas S, Heinzmann K, Bollineni VR, Kramer GM, Liu Y, Waterton JC, Aboagye EO, Shields AF, Soloviev D, Jacobs AH.

Theranostics. 2017 Jan 1;7(1):40-50. doi: 10.7150/thno.16676. eCollection 2017. Review.

10.

A comparative assessment of preclinical chemotherapeutic response of tumors using quantitative non-Gaussian diffusion MRI.

Xu J, Li K, Smith RA, Waterton JC, Zhao P, Ding Z, Does MD, Manning HC, Gore JC.

Magn Reson Imaging. 2017 Apr;37:195-202. doi: 10.1016/j.mri.2016.12.002. Epub 2016 Dec 3.

11.

Bone Area Provides a Responsive Outcome Measure for Bone Changes in Short-term Knee Osteoarthritis Studies.

Bowes MA, Maciewicz RA, Waterton JC, Hunter DJ, Conaghan PG.

J Rheumatol. 2016 Dec;43(12):2179-2182. Epub 2016 Oct 1.

PMID:
27909144
12.

Imaging biomarker roadmap for cancer studies.

O'Connor JP, Aboagye EO, Adams JE, Aerts HJ, Barrington SF, Beer AJ, Boellaard R, Bohndiek SE, Brady M, Brown G, Buckley DL, Chenevert TL, Clarke LP, Collette S, Cook GJ, deSouza NM, Dickson JC, Dive C, Evelhoch JL, Faivre-Finn C, Gallagher FA, Gilbert FJ, Gillies RJ, Goh V, Griffiths JR, Groves AM, Halligan S, Harris AL, Hawkes DJ, Hoekstra OS, Huang EP, Hutton BF, Jackson EF, Jayson GC, Jones A, Koh DM, Lacombe D, Lambin P, Lassau N, Leach MO, Lee TY, Leen EL, Lewis JS, Liu Y, Lythgoe MF, Manoharan P, Maxwell RJ, Miles KA, Morgan B, Morris S, Ng T, Padhani AR, Parker GJ, Partridge M, Pathak AP, Peet AC, Punwani S, Reynolds AR, Robinson SP, Shankar LK, Sharma RA, Soloviev D, Stroobants S, Sullivan DC, Taylor SA, Tofts PS, Tozer GM, van Herk M, Walker-Samuel S, Wason J, Williams KJ, Workman P, Yankeelov TE, Brindle KM, McShane LM, Jackson A, Waterton JC.

Nat Rev Clin Oncol. 2017 Mar;14(3):169-186. doi: 10.1038/nrclinonc.2016.162. Epub 2016 Oct 11. Review.

13.

Investigating the Vascular Phenotype of Subcutaneously and Orthotopically Propagated PC3 Prostate Cancer Xenografts Using Combined Carbogen Ultrasmall Superparamagnetic Iron Oxide MRI.

Burrell JS, Walker-Samuel S, Boult JK, Baker LC, Jamin Y, Halliday J, Waterton JC, Robinson SP.

Top Magn Reson Imaging. 2016 Oct;25(5):237-243. Review.

14.

T1 Relaxation Time in Lungs of Asymptomatic Smokers.

Alamidi DF, Kindvall SS, Hubbard Cristinacce PL, McGrath DM, Young SS, Naish JH, Waterton JC, Wollmer P, Diaz S, Olsson M, Hockings PD, Lagerstrand KM, Parker GJ, Olsson LE.

PLoS One. 2016 Mar 9;11(3):e0149760. doi: 10.1371/journal.pone.0149760. eCollection 2016.

15.

Oxygen-Enhanced MRI Accurately Identifies, Quantifies, and Maps Tumor Hypoxia in Preclinical Cancer Models.

O'Connor JP, Boult JK, Jamin Y, Babur M, Finegan KG, Williams KJ, Little RA, Jackson A, Parker GJ, Reynolds AR, Waterton JC, Robinson SP.

Cancer Res. 2016 Feb 15;76(4):787-95. doi: 10.1158/0008-5472.CAN-15-2062. Epub 2015 Dec 9.

16.

COPD Patients Have Short Lung Magnetic Resonance T1 Relaxation Time.

Alamidi DF, Morgan AR, Hubbard Cristinacce PL, Nordenmark LH, Hockings PD, Lagerstrand KM, Young SS, Naish JH, Waterton JC, Maguire NC, Olsson LE, Parker GJ.

COPD. 2016;13(2):153-9. doi: 10.3109/15412555.2015.1048851. Epub 2015 Oct 21.

PMID:
26488310
17.

Dependence of DCE-MRI biomarker values on analysis algorithm.

Ng CS, Wei W, Bankson JA, Ravoori MK, Han L, Brammer DW, Klumpp S, Waterton JC, Jackson EF.

PLoS One. 2015 Jul 24;10(7):e0130168. doi: 10.1371/journal.pone.0130168. eCollection 2015.

18.

Apparent diffusion coefficient is highly reproducible on preclinical imaging systems: Evidence from a seven-center multivendor study.

Doblas S, Almeida GS, Blé FX, Garteiser P, Hoff BA, McIntyre DJ, Wachsmuth L, Chenevert TL, Faber C, Griffiths JR, Jacobs AH, Morris DM, O'Connor JP, Robinson SP, Van Beers BE, Waterton JC.

J Magn Reson Imaging. 2015 Dec;42(6):1759-64. doi: 10.1002/jmri.24955. Epub 2015 May 26.

PMID:
26012876
19.

Exploring the biomechanical properties of brain malignancies and their pathologic determinants in vivo with magnetic resonance elastography.

Jamin Y, Boult JKR, Li J, Popov S, Garteiser P, Ulloa JL, Cummings C, Box G, Eccles SA, Jones C, Waterton JC, Bamber JC, Sinkus R, Robinson SP.

Cancer Res. 2015 Apr 1;75(7):1216-1224. doi: 10.1158/0008-5472.CAN-14-1997. Epub 2015 Feb 11.

20.

Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome.

O'Connor JP, Rose CJ, Waterton JC, Carano RA, Parker GJ, Jackson A.

Clin Cancer Res. 2015 Jan 15;21(2):249-57. doi: 10.1158/1078-0432.CCR-14-0990. Epub 2014 Nov 24. Review.

21.

Feasibility assessment of using oxygen-enhanced magnetic resonance imaging for evaluating the effect of pharmacological treatment in COPD.

Morgan AR, Parker GJ, Roberts C, Buonaccorsi GA, Maguire NC, Hubbard Cristinacce PL, Singh D, Vestbo J, Bjermer L, Jögi J, Taib Z, Sarv J, Bruijnzeel PL, Olsson LE, Bondesson E, Nihlén U, McGrath DM, Young SS, Waterton JC, Nordenmark LH.

Eur J Radiol. 2014 Nov;83(11):2093-101. doi: 10.1016/j.ejrad.2014.08.004. Epub 2014 Aug 17.

PMID:
25176287
22.

Tumour biomechanical response to the vascular disrupting agent ZD6126 in vivo assessed by magnetic resonance elastography.

Li J, Jamin Y, Boult JK, Cummings C, Waterton JC, Ulloa J, Sinkus R, Bamber JC, Robinson SP.

Br J Cancer. 2014 Apr 2;110(7):1727-32. doi: 10.1038/bjc.2014.76. Epub 2014 Feb 25.

23.

Gadofosveset-based biomarker of tissue albumin concentration: Technical validation in vitro and feasibility in vivo.

Richardson OC, Bane O, Scott ML, Tanner SF, Waterton JC, Sourbron SP, Carroll TJ, Buckley DL.

Magn Reson Med. 2015 Jan;73(1):244-53. doi: 10.1002/mrm.25128. Epub 2014 Feb 11.

24.

Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.

Beloueche-Babari M, Jamin Y, Arunan V, Walker-Samuel S, Revill M, Smith PD, Halliday J, Waterton JC, Barjat H, Workman P, Leach MO, Robinson SP.

Br J Cancer. 2013 Sep 17;109(6):1562-9. doi: 10.1038/bjc.2013.456. Epub 2013 Aug 13.

25.

Noninvasive tumor hypoxia measurement using magnetic resonance imaging in murine U87 glioma xenografts and in patients with glioblastoma.

Linnik IV, Scott ML, Holliday KF, Woodhouse N, Waterton JC, O'Connor JP, Barjat H, Liess C, Ulloa J, Young H, Dive C, Hodgkinson CL, Ward T, Roberts D, Mills SJ, Thompson G, Buonaccorsi GA, Cheung S, Jackson A, Naish JH, Parker GJ.

Magn Reson Med. 2014 May;71(5):1854-62. doi: 10.1002/mrm.24826. Epub 2013 Jun 24.

PMID:
23798369
26.

Indexed distribution analysis for improved significance testing of spatially heterogeneous parameter maps: application to dynamic contrast-enhanced MRI biomarkers.

Rose CJ, O'Connor JP, Cootes TF, Taylor CJ, Jayson GC, Parker GJ, Waterton JC.

Magn Reson Med. 2014 Mar;71(3):1299-311. doi: 10.1002/mrm.24755.

PMID:
23666778
27.

Assessment of gadoxetate DCE-MRI as a biomarker of hepatobiliary transporter inhibition.

Ulloa JL, Stahl S, Yates J, Woodhouse N, Kenna JG, Jones HB, Waterton JC, Hockings PD.

NMR Biomed. 2013 Oct;26(10):1258-70. doi: 10.1002/nbm.2946. Epub 2013 Apr 7.

28.

Improving the diagnosis and management of neuroendocrine tumors: utilizing new advances in biomarker and molecular imaging science.

Giandomenico V, Modlin IM, Pontén F, Nilsson M, Landegren U, Bergqvist J, Khan MS, Millar RP, Långström B, Borlak J, Eriksson B, Nielsen B, Baltzer L, Waterton JC, Ahlström H, Öberg K.

Neuroendocrinology. 2013;98(1):16-30. doi: 10.1159/000348832. Epub 2013 Jun 28.

29.

Exploring ΔR(2) * and ΔR(1) as imaging biomarkers of tumor oxygenation.

Burrell JS, Walker-Samuel S, Baker LC, Boult JK, Jamin Y, Halliday J, Waterton JC, Robinson SP.

J Magn Reson Imaging. 2013 Aug;38(2):429-34. doi: 10.1002/jmri.23987. Epub 2013 Jan 4.

PMID:
23293077
30.

Magnetic resonance transverse relaxation time T2 of knee cartilage in osteoarthritis at 3-T: a cross-sectional multicentre, multivendor reproducibility study.

Balamoody S, Williams TG, Wolstenholme C, Waterton JC, Bowes M, Hodgson R, Zhao S, Scott M, Taylor CJ, Hutchinson CE.

Skeletal Radiol. 2013 Apr;42(4):511-20. doi: 10.1007/s00256-012-1511-5. Epub 2012 Sep 28.

PMID:
23053200
31.

MRI measurements of vessel calibre in tumour xenografts: comparison with vascular corrosion casting.

Burrell JS, Bradley RS, Walker-Samuel S, Jamin Y, Baker LC, Boult JK, Withers PJ, Halliday J, Waterton JC, Robinson SP.

Microvasc Res. 2012 Nov;84(3):323-9. doi: 10.1016/j.mvr.2012.08.001. Epub 2012 Aug 18.

32.

Characterizing tumor response to chemotherapy at various length scales using temporal diffusion spectroscopy.

Xu J, Li K, Smith RA, Waterton JC, Zhao P, Chen H, Does MD, Manning HC, Gore JC.

PLoS One. 2012;7(7):e41714. doi: 10.1371/journal.pone.0041714. Epub 2012 Jul 24.

33.

False-negative MRI biomarkers of tumour response to targeted cancer therapeutics.

Boult JK, Jamin Y, Jacobs V, Gilmour LD, Walker-Samuel S, Halliday J, Elvin P, Ryan AJ, Waterton JC, Robinson SP.

Br J Cancer. 2012 Jun 5;106(12):1960-6. doi: 10.1038/bjc.2012.208. Epub 2012 May 17.

34.

Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging.

Leach MO, Morgan B, Tofts PS, Buckley DL, Huang W, Horsfield MA, Chenevert TL, Collins DJ, Jackson A, Lomas D, Whitcher B, Clarke L, Plummer R, Judson I, Jones R, Alonzi R, Brunner T, Koh DM, Murphy P, Waterton JC, Parker G, Graves MJ, Scheenen TW, Redpath TW, Orton M, Karczmar G, Huisman H, Barentsz J, Padhani A; Experimental Cancer Medicine Centres Imaging Network Steering Committee.

Eur Radiol. 2012 Jul;22(7):1451-64. doi: 10.1007/s00330-012-2446-x. Epub 2012 May 7.

PMID:
22562143
35.

Reproducibility and comparison of DCE-MRI and DCE-CT perfusion parameters in a rat tumor model.

Ng CS, Waterton JC, Kundra V, Brammer D, Ravoori M, Han L, Wei W, Klumpp S, Johnson VE, Jackson EF.

Technol Cancer Res Treat. 2012 Jun;11(3):279-88. Epub 2012 Mar 15.

PMID:
22417064
36.

Comparisons of the efficacy of a Jak1/2 inhibitor (AZD1480) with a VEGF signaling inhibitor (cediranib) and sham treatments in mouse tumors using DCE-MRI, DW-MRI, and histology.

Loveless ME, Lawson D, Collins M, Nadella MV, Reimer C, Huszar D, Halliday J, Waterton JC, Gore JC, Yankeelov TE.

Neoplasia. 2012 Jan;14(1):54-64.

37.

Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas.

Burrell JS, Walker-Samuel S, Baker LC, Boult JK, Jamin Y, Ryan AJ, Waterton JC, Halliday J, Robinson SP.

Int J Cancer. 2012 Oct 15;131(8):1854-62. doi: 10.1002/ijc.27460. Epub 2012 Mar 22.

38.

Apparent diffusion coefficient from magnetic resonance imaging as a biomarker in oncology drug development.

Sinkus R, Van Beers BE, Vilgrain V, DeSouza N, Waterton JC.

Eur J Cancer. 2012 Mar;48(4):425-31. doi: 10.1016/j.ejca.2011.11.034. Epub 2012 Jan 5. Review.

PMID:
22226479
39.

Qualification of imaging biomarkers for oncology drug development.

Waterton JC, Pylkkanen L.

Eur J Cancer. 2012 Mar;48(4):409-15. doi: 10.1016/j.ejca.2011.11.037. Epub 2012 Jan 5. Review.

PMID:
22226478
40.

Overcoming the low relaxivity of gadofosveset at high field with spin locking.

Richardson OC, Scott ML, Tanner SF, Waterton JC, Buckley DL.

Magn Reson Med. 2012 Oct;68(4):1234-8. doi: 10.1002/mrm.23316. Epub 2011 Dec 9.

41.

A quantitative comparison of the influence of individual versus population-derived vascular input functions on dynamic contrast enhanced-MRI in small animals.

Loveless ME, Halliday J, Liess C, Xu L, Dortch RD, Whisenant J, Waterton JC, Gore JC, Yankeelov TE.

Magn Reson Med. 2012 Jan;67(1):226-36. doi: 10.1002/mrm.22988. Epub 2011 Jun 17.

42.

Comparison of dynamic contrast-enhanced MRI and dynamic contrast-enhanced CT biomarkers in bladder cancer.

Naish JH, McGrath DM, Bains LJ, Passera K, Roberts C, Watson Y, Cheung S, Taylor MB, Logue JP, Buckley DL, Tessier J, Young H, Waterton JC, Parker GJ.

Magn Reson Med. 2011 Jul;66(1):219-26. doi: 10.1002/mrm.22774. Epub 2011 Mar 24.

43.

Quantitative imaging test approval and biomarker qualification: interrelated but distinct activities.

Buckler AJ, Bresolin L, Dunnick NR, Sullivan DC, Aerts HJ, Bendriem B, Bendtsen C, Boellaard R, Boone JM, Cole PE, Conklin JJ, Dorfman GS, Douglas PS, Eidsaunet W, Elsinger C, Frank RA, Gatsonis C, Giger ML, Gupta SN, Gustafson D, Hoekstra OS, Jackson EF, Karam L, Kelloff GJ, Kinahan PE, McLennan G, Miller CG, Mozley PD, Muller KE, Patt R, Raunig D, Rosen M, Rupani H, Schwartz LH, Siegel BA, Sorensen AG, Wahl RL, Waterton JC, Wolf W, Zahlmann G, Zimmerman B.

Radiology. 2011 Jun;259(3):875-84. doi: 10.1148/radiol.10100800. Epub 2011 Feb 15.

44.

Investigating temporal fluctuations in tumor vasculature with combined carbogen and ultrasmall superparamagnetic iron oxide particle (CUSPIO) imaging.

Burrell JS, Walker-Samuel S, Baker LC, Boult JK, Ryan AJ, Waterton JC, Halliday J, Robinson SP.

Magn Reson Med. 2011 Jul;66(1):227-34. doi: 10.1002/mrm.22779. Epub 2011 Feb 8.

45.

Comparison of 3T MR scanners in regional cartilage-thickness analysis in osteoarthritis: a cross-sectional multicenter, multivendor study.

Balamoody S, Williams TG, Waterton JC, Bowes M, Hodgson R, Taylor CJ, Hutchinson CE.

Arthritis Res Ther. 2010;12(5):R202. doi: 10.1186/ar3174. Epub 2010 Oct 28.

46.

Multiple-bolus dynamic contrast-enhanced MRI in the pancreas during a glucose challenge.

Naish JH, Hutchinson CE, Caunce A, Roberts C, Waterton JC, Hockings PD, Taylor CJ, Parker GJ.

J Magn Reson Imaging. 2010 Sep;32(3):622-8. doi: 10.1002/jmri.22281.

PMID:
20815060
47.

Measurement of arterial plasma oxygenation in dynamic oxygen-enhanced MRI.

Kershaw LE, Naish JH, McGrath DM, Waterton JC, Parker GJ.

Magn Reson Med. 2010 Dec;64(6):1838-42. doi: 10.1002/mrm.22571.

48.

Tracer kinetic analysis of dynamic contrast-enhanced MRI and CT bladder cancer data: A preliminary comparison to assess the magnitude of water exchange effects.

Bains LJ, McGrath DM, Naish JH, Cheung S, Watson Y, Taylor MB, Logue JP, Parker GJ, Waterton JC, Buckley DL.

Magn Reson Med. 2010 Aug;64(2):595-603. doi: 10.1002/mrm.22430.

49.

Anatomically corresponded regional analysis of cartilage in asymptomatic and osteoarthritic knees by statistical shape modelling of the bone.

Williams TG, Holmes AP, Waterton JC, Maciewicz RA, Hutchinson CE, Moots RJ, Nash AF, Taylor CJ.

IEEE Trans Med Imaging. 2010 Aug;29(8):1541-59. doi: 10.1109/TMI.2010.2047653. Epub 2010 Apr 8.

PMID:
20378463
50.

Measurement and visualisation of focal cartilage thickness change by MRI in a study of knee osteoarthritis using a novel image analysis tool.

Williams TG, Holmes AP, Bowes M, Vincent G, Hutchinson CE, Waterton JC, Maciewicz RA, Taylor CJ.

Br J Radiol. 2010 Nov;83(995):940-8. doi: 10.1259/bjr/68875123. Epub 2010 Mar 11.

Supplemental Content

Loading ...
Support Center